Quantum BioPharma (NASDAQ: QNTM) reported the results of its November 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on November 9. The meeting outcomes and the placement were disclosed in a press release carried by NEWMEDIAWIRE.
Shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved several resolutions. These included authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change. The board retains discretion over implementing the authorized measures.
The company also issued 26 Class A multiple voting shares at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares increased from approximately 57.01% to 68.22%. The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes.
The increase in insider voting control is a key takeaway for investors. With Class A multiple voting shares now representing about 68.22% of aggregate voting power, the CEO and a director have greater influence over future shareholder votes, including any decision to implement the approved consolidation or name change. That concentration may affect how minority holders view governance and could influence the company's access to capital or strategic partnerships. The private placement itself raised only C$80.86, so its significance lies in voting control rather than new funding.
For the biopharmaceutical sector, the approvals give Quantum BioPharma flexibility to adjust its capital structure and equity compensation as it advances its pipeline. The company is focused on treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is developing lead compound Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
The company's shares trade on Nasdaq under the symbol QNTM, and a profile of Quantum BioPharma (NASDAQ: QNTM) is available through BioMedWire. Additional details on the meeting and placement can be found in the full release at https://ibn.fm/UagXR, and the latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The company noted that certain statements are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially.
